Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced it has received CE Mark for Ortho’s VITROS® XT MicroSlide, a new multi-test technology that allows labs to run two tests simultaneously.

Ortho’s VITROS® XT MicroSlide is powered by DIGITAL CHEMISTRYTM, an optics technology that gleans significantly more information from each test than before, improving performance, saving time and space in the lab, and increasing productivity, with less patient sample required for testing. This is an important advantage for vulnerable patients or those with venous access issues.

Jennifer Paine, head of business fields at Ortho said, "Groundbreaking VITROS XT MicroSlides harness the power of our proprietary MicroSlide technology, delivering high-quality test results and higher throughput, all within the lab’s existing physical footprint. Performing two tests per slide reduces the sample volume over current technology. This approach allows timely reporting – especially important for complex, challenging or delicate patients."

Dr. Jorge Aldunate Ortega, clinical laboratory manager of RedSalud in Chile said, "The Ortho VITROS XT MicroSlide is a great technological leap, with DIGITAL CHEMISTRY signifying a true revolution in the pursuit of consistently reliable and accurate clinical diagnoses. This technology reinforces Ortho as the trusted leader in the field of chemistry and immunodiagnostics."  

Ortho’s VITROS® XT MicroSlides, which include VITROS® XT UREA-CREA, TRIG-CHOL and GLU-Ca Slides, have received CE Mark signifying conformance to applicable European Union regulatory requirements. These products are available on the VITROS® XT 7600 Integrated System for purchase in March 2019.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.